{"name":"Mesoblast","slug":"mesoblast","ticker":"MSB.AX","exchange":"ASX","domain":"mesoblast.com","description":"Mesoblast Limited is an Australian regenerative medicine company. It seeks to provide treatments for inflammatory ailments, cardiovascular disease, and back pain. The company is led by Silviu Itescu, who founded the company in 2004.","hq":"Melbourne, Victoria, Australia","founded":2004,"employees":"81","ceo":"Silviu Itescu","sector":"Cell Therapy / Regenerative Medicine","stockPrice":2.02,"stockChange":0.03,"stockChangePercent":1.51,"marketCap":"$2.6B","metrics":{"revenue":85000000,"revenueGrowth":1526.8,"grossMargin":-35.5,"rdSpend":0,"netIncome":-94370000,"cash":129975000,"dividendYield":0,"peRatio":27.1,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Ryoncil patent cliff ($1.4B at risk)","drug":"Ryoncil","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"Remestemcel-L patent cliff ($13.4M at risk)","drug":"Remestemcel-L","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"Allogeneic Mesenchymal Precursor Cells","genericName":"Allogeneic Mesenchymal Precursor Cells","slug":"allogeneic-mesenchymal-precursor-cells","indication":"Other","status":"phase_2"},{"name":"Standard of Care for GVHD","genericName":"Standard of Care for GVHD","slug":"standard-of-care-for-gvhd","indication":"Graft-versus-host disease","status":"phase_3"},{"name":"Prochymal®","genericName":"Prochymal®","slug":"prochymal","indication":"Graft-versus-host disease","status":"phase_3"},{"name":"Provacel","genericName":"Provacel","slug":"provacel","indication":"Other","status":"phase_1"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Rexlemestrocel-L + HA Mixture","genericName":"Rexlemestrocel-L + HA Mixture","slug":"rexlemestrocel-l-ha-mixture","indication":"Knee osteoarthritis","status":"phase_3"}]}],"pipeline":[{"name":"Allogeneic Mesenchymal Precursor Cells","genericName":"Allogeneic Mesenchymal Precursor Cells","slug":"allogeneic-mesenchymal-precursor-cells","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Rexlemestrocel-L + HA Mixture","genericName":"Rexlemestrocel-L + HA Mixture","slug":"rexlemestrocel-l-ha-mixture","phase":"phase_3","mechanism":"Rexlemestrocel-L is an allogeneic mesenchymal stem cell therapy combined with hyaluronic acid that promotes tissue repair and reduces inflammation through paracrine signaling and immunomodulation.","indications":["Knee osteoarthritis","Tendon and ligament injuries"],"catalyst":""},{"name":"Standard of Care for GVHD","genericName":"Standard of Care for GVHD","slug":"standard-of-care-for-gvhd","phase":"phase_3","mechanism":"Rexlemestrocel-L is a mesenchymal stem cell therapy that modulates the immune system to treat graft-versus-host disease.","indications":["Graft-versus-host disease"],"catalyst":""},{"name":"Prochymal®","genericName":"Prochymal®","slug":"prochymal","phase":"phase_3","mechanism":"Prochymal is a mesenchymal stem cell therapy that aims to modulate the immune system and promote tissue repair.","indications":["Graft-versus-host disease"],"catalyst":""},{"name":"Provacel","genericName":"Provacel","slug":"provacel","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Mesoblast Reports FY2023 Financial Results","summary":"Mesoblast reported a net loss of $1.4 billion for FY2023, with revenue of $13.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-12-14","type":"deal","headline":"Mesoblast Announces Collaboration with Pfizer","summary":"Mesoblast and Pfizer announced a collaboration to develop and commercialize Mesoblast's cell therapy products.","drugName":"","sentiment":"positive"},{"date":"2023-11-15","type":"regulatory","headline":"FDA Approves Ryoncil for Graft-Versus-Host Disease","summary":"The FDA approved Ryoncil for the treatment of graft-versus-host disease in patients 2 years and older.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOZjZCS0oydUtqVURzd0dXNF94dGxBM1RsZ0E5TDdwZ1dxN29zVXBUWjB0YjN2WHExYW1yVXI4dzhQUWNQeDIxWUhyMDA2LUo4UDVGMmZRNTMwdEhiUE1lU2RkckhsSFdpSUVqVDMzRTZDSVItUklucFI4SU9oTk1BbVdn?oc=5","date":"2025-12-17","type":"deal","source":"The Motley Fool Australia","summary":"5 ASX shares I'd buy with $10,000 this week - The Motley Fool Australia","headline":"5 ASX shares I'd buy with $10,000 this week","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOVFBYTUFDUjN2SnU1dFBpNTVfTnpCZDZ3Q0l6cjFoWXVkRDluMG92WnBQOVdBUWxnM09DeUhpaDE5QmktS25RdEtVLXdhLXh3OUt1VFZKdURUeldBSWswclRpX3hiNjRxZVlvVEhTbXF0eDJHMENSYncxbThkYThPM25MUzh4Q28?oc=5","date":"2025-11-11","type":"pipeline","source":"Yahoo Finance","summary":"Mesoblast Limited (ASX:MSB): Are Analysts Optimistic? - Yahoo Finance","headline":"Mesoblast Limited (ASX:MSB): Are Analysts Optimistic?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQVkh1akpJd2ZvbE1TUUxkd3dELVE0bWM1V1RuTU42akFCQ3JRY2pfZmZNTE90bS1zaXZuRDZTVjZXMUJyRUxvVGxpdWFUMFdOVWJEVkJodFBhNndWVWk0OTVucU9oRWJFSFRZWndDeWMtYlVLREE0ZzhHZGlaQUkweWFFdWZ0RFlsLVEtUkRmVFhtSlNWQmZzNkktMVRXNG9jVmxnNEg2TmtKSkdDR2twUTAzQlJNUQ?oc=5","date":"2025-09-29","type":"pipeline","source":"Stockhead","summary":"Health Check: Biotech investors reckon Trump’s tariffs may not be such a bitter pill - Stockhead","headline":"Health Check: Biotech investors reckon Trump’s tariffs may not be such a bitter pill","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-15","type":"deal","source":"simplywall.st","summary":"Insider Stock Buying Reaches US$201.4m On Mesoblast - simplywall.st","headline":"Insider Stock Buying Reaches US$201.4m On Mesoblast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxQQ0p1akxLdXRkVWdJM0t1MkdtaWVWdEJrWUEwMkZsd1MtbTM4c0VIVFItUU5HZGJ4M0xaSGFYQnhlbzZEQncycS0tTHV1SGFwYWlFODh3REUtbURZNGJGM05SX3MxeDBGY1RqemcxS2RnU1YxUDluRDVPaklkSUZJWVVpSlhOby04cDZXb2xwOUw2Rlg5Sy1hRjVqdEVjbzhxMGlENG03UXZCOG5KTEN6c0J4OWlEVmdLS1RocFF1Y1Jod0xTeW41UTJncXgtc3YzQlcw?oc=5","date":"2024-12-19","type":"regulatory","source":"Reuters","summary":"US FDA approves Mesoblast's cell therapy for graft-versus-host disease - Reuters","headline":"US FDA approves Mesoblast's cell therapy for graft-versus-host disease","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE54aWgzcWFGLTZZbFdjbHJkV3NTNDF2c1YwRmY4UFdHNGRPMmNUUWE3dWNreTA1MV9YMHBlMDljRUJuMXlWTTZEa2ZyY1ExMHFCcFh4UGp3dC1BWktOR01R?oc=5","date":"2017-07-06","type":"trial","source":"Yahoo Finance Australia","summary":"Mesoblast Limited (MSB.AX) stock historical prices and data - Yahoo Finance Australia","headline":"Mesoblast Limited (MSB.AX) stock historical prices and data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE5BWWZvNXlKWUVOVHRyT3FuRTJkQUJuY05VbU1XMEZCZzdKcXRndm9Ial9wTnkxMmdpMENCaU1HNnAyNzY5UXZCWVdJS0JRMTBLSU03TA?oc=5","date":"2017-05-29","type":"pipeline","source":"Yahoo Finance Australia","summary":"Opthea Limited (OPT.AX) stock price, news, quote and history - Yahoo Finance Australia","headline":"Opthea Limited (OPT.AX) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE1UUEdudldhT1dlNFdhZ3FfQTJpdGdXOUhwM2NGUTh1QWRWN1JWX0dIdFRSRVJZV0VQRkVDOHAzVFNLemU3OThFU2xjdDNFTkVZaEYwTQ?oc=5","date":"2017-05-25","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Mayne Pharma Group Limited (MYX.AX) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Mayne Pharma Group Limited (MYX.AX) stock price, news, quote and history","sentiment":"neutral"}],"patents":[{"drugName":"Ryoncil","drugSlug":"ryoncil","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"Remestemcel-L","drugSlug":"remestemcel-l","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":13400000}],"drugCount":5,"phaseCounts":{"phase_2":1,"phase_3":3,"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Vertex Pharmaceuticals","Gilead Sciences","Biogen"],"therapeuticFocus":["Cardiovascular","Inflammatory Diseases"],"financials":null,"yahoo":{"currentPrice":2.02,"previousClose":1.99,"fiftyTwoWeekHigh":3.31,"fiftyTwoWeekLow":1.51,"fiftyTwoWeekRange":"1.515 - 3.31","fiftyDayAverage":2.3,"twoHundredDayAverage":2.4,"beta":0.82,"enterpriseValue":2562871296,"forwardPE":27.1,"priceToBook":3.12,"priceToSales":39.81,"enterpriseToRevenue":39.2,"enterpriseToEbitda":-39.83,"pegRatio":0,"ebitda":-64339000,"ebitdaMargin":-98.4,"freeCashflow":-69438336,"operatingCashflow":-59643000,"totalDebt":135144000,"debtToEquity":23.5,"currentRatio":1.58,"returnOnAssets":-6.2,"returnOnEquity":-18.2,"analystRating":"","recommendationKey":"none","numberOfAnalysts":4,"targetMeanPrice":3.9,"targetHighPrice":4.71,"targetLowPrice":3.2,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":36.4,"institutionHeldPercent":16.4,"sharesOutstanding":1288514948,"floatShares":839931354,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":-0.11,"epsForward":0.07,"revenuePerShare":0.05,"bookValue":0.65,"officers":[{"age":68,"name":"Dr. Silviu  Itescu FACP, FACRA, FRACP, MBBS (Hons)","title":"Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director"},{"age":74,"name":"Dr. Eric A. Rose M.D.","title":"Chief Medical Officer & Executive Director"},{"age":59,"name":"Mr. James Michael O'Brien CPA, M.B.A.","title":"Chief Financial Officer"},{"age":57,"name":"Mr. Peter T. Howard B.Sc., L.L.B.","title":"General Counsel & Corporate Executive"},{"age":null,"name":"Mr. Paul  Hughes BPHARM","title":"Global Head of Corporate Communications & Joint Company Secretary"},{"age":66,"name":"Dr. Paul J. Simmons BSc, Ph.D.","title":"Scientific Advisor to the Chief Executive Officer"},{"age":null,"name":"Ms. Geraldine  Storton B.Sc., M.B.A., MMS","title":"Head of Regulatory Affairs & Quality Management"},{"age":null,"name":"Mr. Justin  Horst B.S.","title":"Head of Manufacturing"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.mesoblast.com","phone":"61 3 9639 6036"}}